jRCT2071240025招募中不适用
A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy (CRIMSON)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 主要终点
- Occurrence of a >=2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •General inclusion criteria
- •Diagnosis of DM under regular treatment with Haemoglobin A1c (HbA1c) (glycated haemoglobin) <12%
- •Age >=18 years at time of signing Informed Consent Form
- •Ocular inclusion criteria: study eye
- •Moderately severe to severe non-proliferative diabetic retinopathy (NPDR) (Diabetic Retinopathy Severity Scale (DRSS) 47 to 53) based on early treatment diabetic retinopathy study (ETDRS) 7-field grading as confirmed by the central reading centre (CRC) at screening
- •Presence of retinal non-perfusion (RNP) as assessed by ultra-widefield fluorescein angiography (UWF-FA) defined as an area >=12.5 square millimeter (mm2) (approximately >=5disc areas) within a circular area with a 17.5 millimeter (mm) radius centred to the fovea as confirmed by the CRC at screening
- •Visual acuity, best corrected visual acuity (BCVA) letter score of >=49 letters (approximate Snellen equivalent of 20/100 or better) using ETDRS chart at starting distance of 4 meter (m) at screening
- •Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
排除标准
- •Main exclusion criteria in study eye
- •Evidence of active retinal neovascularisation (NV) on clinical exam and/or ultra-widefield colour fundus photography (UWF-CFP) within the ETDRS 7-field, confirmed by the CRC grading
- •Neovascularisations outside of the ETDRS 7-field on ultra-widefield imaging may be included if this condition, based on the assessment of the investigator, does not require acute treatment
- •Evidence of active NV of the iris (small iris tufts are not an exclusion) or in the anterior chamber angle
- •Prior pan-retinal photocoagulation (PRP) (defined as >=100 burns placed previously outside of the posterior pole)
- •CI-DME, defined as a central subfield thickness (CST) >=320 micrometer (men)/305 micrometer (women), measured by Heidelberg Spectralis optical coherence tomography (OCT), in the study eye as confirmed by the CRC at screening
- •Previous treatment in the study eye for NPDR and/or diabetic macular edema (DME) with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) (including anti-VEGF/Ang2) drugs within 6 months prior to Day
- •The number of patients with history of an IVT anti-VEGF treatment is limited to approximately 50 randomised patients. Once this number has been achieved, any patients with previous IVT treatment will be excluded
- •Any previous IVT treatment other than anti-VEGF, including steroids
- •Myopia with a refractive error <-8 dioptres (spherical equivalent) in the study eye. For patients having undergone refractive or cataract surgery in the study eye, the preoperative refractive error should be used.
- •Any concurrent or past ocular condition in the study eye which, in the judgement of the investigator, could:
- •Require medical or surgical intervention during the study period to prevent or treat vision loss (e.g. advanced cataract, history of retinal detachment or macular hole (Stage 3 or 4) in the study eye)
- •Could likely contribute to a significant loss of BCVA during the study period if left untreated (e.g. advanced epiretinal membrane and/or vitreomacular traction, active or history of optic neuritis in either eye)
- •Contraindicate the use of the investigational drug, or may render the patient at high risk for treatment complications (e.g. active infectious or non-infectious conjunctivitis/keratitis in either eye; history of recurrent infectious or inflammatory ocular disease in either eye (e.g. uveitis)
- •May affect interpretation of the study results (e.g. central atrophy of the retinal pigment epithelium or photoreceptors; age-related macular degeneration, hereditary retinal degenerative diseases, myopic macular degeneration, past, current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. deferoxamine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol); history of central serous chorioretinopathy, ischemic optic neuropathy or retinal vascular occlusion
结局指标
主要结局
Occurrence of a >=2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52
时间窗: At baseline and at Week 52
The DRSS is a scale which can take on the following discrete values: 10, 20, 35, 43, 47, 53, 61, 65, 71, 75, 81, 85. Here 10 means "No retinopathy" and 85 means "Advanced proliferative diabetic retinopathy, with posterior fundus obscured, or centre of macula detached". Thus, a higher score means symptoms get worse.
次要结局
- Absolute change from baseline of best corrected visual acuity (BCVA) [early treatment diabetic retinopathy study (ETDRS) letters] in the study eye at Week 52(At baseline and at Week 52)
- Occurrence of a >=2-step worsening of Diabetic Retinopathy Severity Scale (DRSS) in the study eye between baseline and Week 52(At baseline and at Week 52)
研究者
相似试验
已完成
1 期
A study in healthy people to test how BI 1015550 is taken up in the body when given with or without food2023-509889-38-00Boehringer Ingelheim International GmbH18
招募中
不适用
A study to test whether BI 690517 in combination with empagliflozin helps people with heart failure (EASi-HF)Heart FailurejRCT2051240109Boehringer Ingelheim300
招募中
不适用
A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with
head and neck cancer compared with pembrolizumab alonejRCT2011240074Nippon Boehringer Ingelheim Co., Ltd.6
已完成
1 期
A study in healthy men to test how BI 1569912 is processed in the body2023-510464-12-00Boehringer Ingelheim International GmbH8
已完成
1 期
A study in healthy men to test how BI 764198 is processed in the body2022-502327-22-00Boehringer Ingelheim International GmbH16